Effects of vitamin D on bone and muscle density in myasthenia gravis patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12617000445370

Enrollment

100

Registered

2017-03-27

Start date

2017-02-08

Completion date

Unknown

Last updated

2017-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The expected outcomes will demonstrate the effects after supplement of vitamin D by ages and genders of MG patients with in-depth understanding integrating dietitian, radiologist, pharmacist, respiratory therapist, and clinical psychologist. This multidimensional project will provide empirical evidence to clinical specialists related to the demands and effects of the supplementation of vitamin D for MG patients.

Interventions

Vit D 3 administration a) the dose administered:2 drops once daily (400 iu/drop) b) the duration of administration:12 weeks c) the mode of administration:oral drop

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

myasthenia gravis patients

Exclusion criteria

Pregnant women, mental disorder

Outcome results